ZyVersa Therapeutics announces developments on inflammasome inhibitors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2025
0mins
ZyVersa Therapeutics' IC 100 Development: ZyVersa Therapeutics is advancing its inflammasome ASC inhibitor, IC 100, as a complementary therapy to GLP-1 agonists for treating obesity-related cardiometabolic issues, addressing significant unmet medical needs such as muscle loss and high discontinuation rates of GLP-1 treatments due to gastrointestinal side effects.
Preclinical Data and Future Plans: Preclinical studies show IC 100's potential in reducing inflammation and improving metabolic parameters, with a comprehensive development plan that includes initiating preclinical studies and submitting an Investigational New Drug application by 2025, aiming to enhance weight loss and mitigate obesity-associated comorbidities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
